How Will Biotech ETFs Finish Out The Year? [Biogen Idec Inc, Celgene Corporation, Amgen, Inc., Merck & Co., Inc.]

biotechThe Biotechnology ETF world has been on a roller coaster ride this year. After peaking at the beginning of March, the space saw a huge sell-off until the middle of April, after which it has seen some recovery in the past two months.
NASDAQ:BIB June 18, 2014 4:48pm

5 Biotech Stocks That Could Double [Ariad Pharmaceuticals, Inc., Infosys Ltd ADR, Idenix Pharmaceuticals Inc]

biotechBillionaires Portfolio: This week the biotech stock Idenix Pharmaceuticals Inc (NASDAQ:IDIX) was acquired by Merck for a 229% premium. That’s one of the biggest one day moves ever, for a stock listed on the New York Stock Exchange.
NASDAQ:BIB June 13, 2014 12:14pm

Potential Upside In Canadian Biotech [Alexion Pharmaceuticals, Inc., Celgene Corporation, Merck & Co., Inc.]

biotechnologyYou may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling skill sets and pipelines.
NASDAQ:BIB June 12, 2014 3:51pm

Making Huge Profits Following Billionaire Investors [Merck & Co., Inc., Idenix Pharmaceuticals Inc, Celgene Corporation]

money and investingBillionaires Portfolio: Yesterday, Idenix Pharmaceuticals Inc (NASDAQ:IDIX) was acquired by Merck & Co., Inc. (NYSE:MRK) for a 229% premium.  That’s one of the biggest one day moves ever for a stock listed on the New York Stock Exchange.  
NASDAQ:BIB June 10, 2014 12:49pm

7 Biotech Stocks To Watch Closely [AbbVie Inc, AstraZeneca plc (ADR), Celgene Corporation, Achillion Pharmaceuticals, Inc.]

biotechDiane Alter: A number of promising cancer treatments were presented this week by key global pharmaceutical players at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) - which is why this is a key time of year to watch
NASDAQ:BIB June 9, 2014 12:33pm

Cashing In On Biotech [Celgene Corporation, Biogen Idec Inc, Alexion Pharmaceuticals, Inc., Dendreon Corporation]

biotechWhen progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The Maxim Group's Senior Managing Director and Head of Healthcare Jason Kolbert
NASDAQ:BIB June 5, 2014 1:52pm

Hottest Sector In The Drug Development Industry [Bristol-Myers Squibb Co, Amgen, Inc., Celldex Therapeutics, Inc., AstraZeneca plc (ADR)]

drugsWorking in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets. The premier event for those in the field is the American Society of Clinical Oncology annual meeting, taking place in Chicago from May 30 to June 1.
NYSE:XBI May 29, 2014 12:48pm

Turn Solid Gold Into Biotech Gold [Allergan, Inc., AstraZeneca plc (ADR), Pfizer Inc., Gilead Sciences, Inc.]

biotechThe globe-trotting editor and publisher of The Midas Letter has decided to give his metal investments a breather, looking for new prospects in the life sciences space. In this interview with The Life Sciences Report, James West points to low-hanging biofruit ripe for the picking.

How To Make Money With Generics and Diagnostics [Novartis AG (ADR), Gilead Sciences, Inc., AbbVie Inc, Pfizer Inc.]

make-moneyThe concept that generic and specialty pharmaceutical drugs cannot command pricing power and growth is a misunderstanding, according to Director and Senior Analyst Rohit Vanjani of Oppenheimer and Co. Diagnostics also offer upside to investors:
NASDAQ:BIB May 22, 2014 3:02pm

Harnessing The Power Of Nature’s Perfect Cells [Celgene Corporation, StemCells Inc, MYOS Corp]

biotechNeurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report.

Great Biotech Picks For 2014 [Novavax, Inc., Celgene Corporation, Biogen Idec Inc, Alexion Pharmaceuticals, Inc.]

biotech2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing.
NASDAQ:BIB May 21, 2014 2:54pm

iShares NASDAQ Biotechnology Index (ETF) Continues To Be In A Bearish Trend

sellbuyMorpheus Trading: As a potential short selling setup, iShares Nasdaq Biotech ETF (NASDAQ:IBB) remains weak and hasn't budged much since the sharp bounce off the lows in late April. The daily chart below shows resistance of its downtrend line, while the 50-day MA
NASDAQ:IBB May 20, 2014 10:39am

What’s Next For AstraZeneca plc (ADR) (AZN) and Pfizer Inc. (PFE)

whats-nextKyle Anderson: AstraZeneca Plc (NYSE:AZN) stock dropped as much as 15% today (Monday) following news that the British pharmaceutical company had rejected Pfizer Inc.'s (NYSE:PFE) final takeover offer. That's the largest intra-day loss in AZN stock's history.

Biotechs With Big Upside [Gilead Sciences, Inc., Biogen Idec Inc, Alexion Pharmaceuticals, Inc., Celgene Corporation, Novartis AG (ADR)]

biotechnologyA downtrending market is troublesome for investors, but does present interesting opportunities through creation of lower valuations. Finding the right names in the wobbly life sciences environment requires a sharp eye and depth of experience.
NASDAQ:BIB May 15, 2014 4:01pm

Get Free Updates

Join over 50,000 investors who get the latest news from!

Most Popular

From Our Partners

Explore More from

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again! respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories